In fact, the company has exceeded its own expectations in global sales this year and now leads the worldwideÂ market in endovascular aortic repair. By the end of the third quarter, Cook surpassed Gore and captured 40% of the U.S. market (Gore had 35% and Medtronic held 23%). In Europe, Cook took the top spot in AAA stent grafts at 42%. The company is working on several projects for its Zenith Endograft product family for 2008. We can expect to see several clinical trials, PMA submissions, and even product launches in the coming year as Cook tries to keep a tight grip on the market.